Fibrosis-related biomarkers and risk of total and cause-specific mortality

American Journal of Epidemiology

Volumn 179, Issue 11, 2014, Pages 1331-1339

  Agarwal, Isha ^a   Glazer, Nicole L ^b   Barasch, Eddy ^c   Biggs, Mary L ^d   Djoussé, Luc ^e,f   Fitzpatrick, Annette L ^d   Gottdiener, John S ^g   Ix, Joachim H ^h,i   Kizer, Jorge R ^j   Rimm, Eric B ^a,e   Siscovick, David S ^d,k   Tracy, Russell P ^l   Zieman, Susan J ^m   Mukamal, Kenneth J ⁿ  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Division of SCI Research   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^m National Institute of Aging   (United States)

ⁿ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

biomarkers; fibrosis; inflammation; mortality

Indexed keywords

C REACTIVE PROTEIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

BIOMARKER; CARDIOVASCULAR DISEASE; HEALTH RISK; HEALTH SURVEY; MORTALITY; PEPTIDE; PROTEIN; RESPIRATORY DISEASE; RISK FACTOR;

AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR MORTALITY; DISEASE MARKER; FEMALE; HEART MUSCLE FIBROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR;

BIOMARKERS; FIBROSIS; INFLAMMATION; MORTALITY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAUSE OF DEATH; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84901723684     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu067     Document Type: Article

References (32)

1. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012; 18(7):1028-1040.
2. Richeldi L, du Bois RM. Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. Expert Rev Respir Med. 2011;5(4):473-481.
3. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010; 121(14):1645-1654.
4. Pitt B, Zannad F. The detection of myocardial fibrosis: an opportunity to reduce cardiovascular risk in patients with diabetes mellitus? Circ Cardiovasc Imaging. 2012;5(1):9-11.
5. Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol. 2004; 122(1):1-6. (Pubitemid 38114631)
6. Jensen LT, Horslev-Petersen K, Toft P, et al. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation. 1990;81(1): 52-57. (Pubitemid 20031766)
7. Risteli J, Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol. 1995;22(2 suppl):77-81.
8. Teekakirikul P, Eminaga S, Toka O, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-p. J Clin Invest. 2010;120(10):3520-3529.
9. Nakamura T, Sakata R, Ueno T, et al. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology. 2000;32(2):247-255. (Pubitemid 30614657)
10. Fukasawa H, Yamamoto T, Suzuki H, et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int. 2004;65(1):63-74. (Pubitemid 38037492)
11. Toma I, McCaffrey TA. Transforming growth factor-P and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res. 2012;347(1):155-175.
12. Glazer NL, Macy EM, Lumley T, et al. Transforming growth factor beta-1 and incidence of heart failure in older adults: the Cardiovascular Health Study. Cytokine. 2012;60(2): 341-345.
13. Pardali E, Ten Dijke P. TGFp signaling and cardiovascular diseases. Int J Biol Sci. 2012;8(2):195-213.
14. Yang YC, Zhang N, Van Crombruggen K, et al. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 2012; 67(10):1193-1202.
15. Barasch E, Gottdiener JS, Aurigemma G, et al. Association between elevated fibrosis markers and heart failure in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2009;2(4):303-310.
16. Barasch E, Gottdiener JS, Aurigemma G, et al. The relationship between serum markers of collagen turnover and cardiovascular outcome in the elderly: the Cardiovascular Health Study. Circ Heart Fail. 2011;4(6):733-739.
17. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3): 263-276.
18. Fredericks S, Holt DW. TGF-beta quantitation can be tricky. Transplantation. 1999;68(4):468-469.
19. Ives DG, Samuel P, Psaty BM, et al. Agreement between nosologist and cardiovascular health study review of deaths: implications of coding differences. J Am Geriatr Soc. 2009; 57(1):133-139.
20. Psaty BM, Lee M, Savage PJ, et al. Assessing the use of medications in the elderly: Methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group. J Clin Epidemiol. 1992;45(6): 683-692.
21. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524-532.
22. Bertoluci MC, Uebel D, Schmidt A, et al. Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Res Clin Pract. 2006;72(3):258-264. (Pubitemid 43744476)
23. Schaan BD, Quadros AS, Sarmento-Leite R, et al. 'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease. Cardiovasc Diabetol. 2007;6:19.
24. Pfeiffer A, Middelberg-Bisping K, Drewes C, et al. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care. 1996;19(10):1113-1117. (Pubitemid 26334260)
25. Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22(6): 1144-1151.
26. Budd DC, Holmes AM. Targeting TGFβ superfamily ligand accessory proteins as novel therapeutics for chronic lung disorders. Pharmacol Ther. 2012;135(3):279-291.
27. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest. 2009;136(5):1364-1370.
28. Chu HW, Balzar S, Seedorf GJ, et al. Transforming growth factor-beta2 induces bronchial epithelial mucin expression in asthma. Am J Pathol. 2004;165(4):1097-1106. (Pubitemid 39297717)
29. Zhao J, Sime PJ, Bringas P Jr, et al. Adenovirus-mediated decorin gene transfer prevents TGF-beta-induced inhibition of lung morphogenesis. Am J Physiol. 1999;277(2 pt 1): L412-L422. (Pubitemid 29415099)
30. Zhang R, Zhang YY, Huang XR, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010; 55(4):953-960.
31. Sivakumar P, Das AM. Fibrosis, chronic inflammation and new pathways for drug discovery. Inflamm Res. 2008;57(9): 410-418.
32. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 2008;4(3):575-596. (Pubitemid 352037917)